Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with <i>Staphylococcus Aureus</i> by pharmacokinetic/pharmacodynamic analysis-Reference-Cited by-同舟云学术

Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with Staphylococcus Aureus by pharmacokinetic/pharmacodynamic analysis

Published:2024-04-22 Issue: Volume: Page:1-8
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Xu Gaoqi¹,Liu Xin²,Wang Jiaqi¹,Mei Yuqing³⁴,Yang Dihong¹,He Chaoneng¹,Zhong Like¹,Zhu Junfeng¹,Ding Haiying¹,Fang Luo¹

Affiliation:

1. Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China

2. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China

3. Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China

4. Department of Clinical Pharmacology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Funder

Zhejiang Provincial Medical Health Science and Technology Project

the Hospital Pharmacy Special Project of Zhejiang Pharmaceutical Association

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2024.2343963

Reference25 articles.

1. Community-Acquired Pneumonia

2. Omadacycline in treating community-based infections: a review and expert perspective

3. The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance

4. Budget impact of omadacycline for the treatment of patients with community-acquired bacterial pneumonia in the United States from the hospital perspective;LaPensee K;Am Health Drug Benefits,2019

5. Community-acquired bacterial pneumonia in adults: An update